8-K: XOMA Royalty Appoints Jeffrey Trigilio as New CFO

XOMA Royalty Corporation announced the appointment of Jeffrey Trigilio as its new Chief Financial Officer, succeeding Thomas Burns, effective January 12, 2026.

Summary

• Jeffrey Trigilio has been appointed as the new Chief Financial Officer of XOMA Royalty Corporation, effective January 12, 2026.
• Mr. Trigilio, 41, brings extensive experience from leadership roles at Obsidian Therapeutics, Inc. (CFO and COO) and Cullinan Therapeutics, Inc. (CFO), as well as prior experience with Amylyx Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., and in investment banking.
• His compensation package includes an annual base salary of $515,000, an initial target annual cash bonus opportunity of 40% of his base salary, an initial equity grant of 30,000 performance units, and an annual equity grant in 2026 valued at approximately 180,000 multiplied by the common stock closing price on the effective date.
• Thomas Burns stepped down from his position as Senior Vice President, Finance and Chief Financial Officer, effective January 12, 2026, to pursue other professional opportunities.
• Mr. Burns' employment officially ended on January 15, 2026, under a separation and consulting agreement, which provides for severance payments, acceleration of certain performance stock units, and a three-month consulting period at a monthly fee of $16,000.

Sentiment

Score: 7

Explanation: The appointment of an experienced CFO is a positive step for strategic financial management and growth. The transition appears well-managed with a clear succession plan and positive statements from both current and departing executives. However, the departure of a long-serving CFO always carries some inherent uncertainty, even if mitigated by a consulting agreement.

Positives

• The appointment of Jeffrey Trigilio, an experienced financial executive with a strong background in biotech and investment banking, is expected to enhance the company's financial strategy, disciplined capital deployment, and value generation.
• The company's CEO, Owen Hughes, expressed gratitude for Thomas Burns' nearly two decades of service, acknowledging his leadership in building a strong financial foundation, suggesting a well-managed transition.
• Thomas Burns affirmed XOMA Royalty's established position in the biotech royalty segment, highlighting its multiple commercial assets and robust portfolio expected to deliver future milestones and royalty streams.

Negatives

• The departure of Thomas Burns, a long-serving CFO with nearly two decades of experience, could represent a loss of institutional knowledge, despite the positive framing of the transition.
• The company will incur severance and consulting costs associated with Thomas Burns' departure, including a monthly consulting fee of $16,000 for an initial three-month period.

Risks

• Product candidates subject to out-license agreements are still being developed, and licensees may require substantial funds to continue development which may not be available.
• There is no guarantee of a viable market for the products in which XOMA Royalty has an ownership or royalty interest.
• If the therapeutic product candidates to which XOMA Royalty has a royalty interest do not receive regulatory approval, third-party licensees will not be able to market them, which would negatively impact future royalty streams.

Future Outlook

The company anticipates continued execution of a strategy focused on disciplined capital deployment, robust diligence, and innovative deal structuring to enhance its royalty portfolio and generate shareholder value. It also expects its robust portfolio to deliver milestones and additional royalty streams for the foreseeable future.

Management Comments

• "Toms leadership, guidance, and resourcefulness have been invaluable as the Company transitioned to and established itself as a royalty aggregator." Owen Hughes, CEO.
• "On behalf of the Board of Directors and my XOMA Royalty colleagues, I would like to thank Tom for his nearly two decades of service to the Company, his unwavering dedication, and the strong financial foundation he built to support XOMA Royaltys future growth." Owen Hughes, CEO.
• "It has been a great honor to have played a key role in the XOMA Royalty journey. With multiple commercial assets and a robust portfolio that should deliver milestones and additional royalty streams for the foreseeable future, XOMA Royalty is firmly established in the biotech royalty segment of the healthcare ecosystem." Thomas Burns.
• "XOMA Royaltys leadership team has a track record of identifying and capturing underappreciated value across opportunities. Together we will continue to execute a strategy of disciplined capital deployment, robust diligence, and innovative deal structuring to enhance our royalty portfolio and generate value for shareholders." Jeffrey Trigilio.

Industry Context

XOMA Royalty operates as a biotechnology royalty aggregator, a specialized segment within the healthcare ecosystem that provides non-dilutive funding to biotech companies by acquiring future economics from therapeutic candidates. The appointment of a CFO with extensive experience in biotech and investment banking aligns with the industry's need for strategic financial management and deal structuring to navigate complex drug development and commercialization landscapes.

Comparison to Industry Standards

• The compensation package for the new CFO, including a base salary of $515,000, a 40% target bonus, and significant equity grants, appears competitive for a CFO at a publicly traded biotechnology royalty aggregator, especially given the experience cited from other biotech companies like Obsidian Therapeutics and Cullinan Therapeutics.
• The severance terms, including 0.75x base salary for standard termination and 1.5x (base salary + target bonus) for change of control, are within typical ranges for executive employment agreements in the biotech sector, comparable to practices seen at companies like Alexion Pharmaceuticals or Amylyx Pharmaceuticals where the new CFO previously worked.
• The consulting arrangement for the departing CFO, providing transition services for three months at $16,000 per month, is a standard practice to ensure continuity during executive transitions, similar to arrangements observed in other mid-to-large cap biotech firms.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: The appointment of an experienced CFO could enhance financial strategy and potentially drive shareholder value through disciplined capital deployment and deal structuring. The compensation package, including performance-based equity, aims to align the CFO's interests with shareholder returns.
• Employees: The change in CFO signals a leadership transition in the finance department, which could lead to new strategic directions or operational adjustments within that function.
• Customers/Licensees: No direct impact on customers or licensees is indicated by this executive change, but a strong financial leadership team can indirectly support the company's ability to secure and manage royalty agreements.
• Creditors: A stable and experienced financial leadership team, as indicated by the new CFO's background, can instill confidence in the company's financial management and ability to meet obligations.

Next Steps

• The full text of Jeffrey Trigilio's Employment Agreement will be filed as an exhibit to the Company's Annual Report on Form 10-K for the year ended December 31, 2025.
• The full text of Thomas Burns' Separation and Consulting Agreement will be filed as an exhibit to the Company's Annual Report on Form 10-K for the year ended December 31, 2025.
• Jeffrey Trigilio's initial equity grant will vest based on achievement of stock price hurdles over a performance period ending on the earlier of May 18, 2026, or the Company's 2026 annual meeting of stockholders.
• Thomas Burns will provide transition and advisory services as a consultant for an initial three-month period.

Key Dates

Recommendation

The filing details a routine executive transition with the appointment of a new CFO and the departure of the previous one. While the new CFO brings relevant experience, and the transition appears managed, this announcement alone does not provide sufficient new financial or operational data to warrant a 'buy' or 'sell' recommendation. Investors should hold their positions and await further financial reports or strategic updates to assess the impact of this leadership change on the company's performance and outlook. The company's core business as a royalty aggregator remains unchanged, and the risks associated with its portfolio are consistent with previous disclosures.

Keywords

XOMA Royalty, CFO appointment, Jeffrey Trigilio, Thomas Burns, biotech royalty, financial officer, corporate governance, executive change, Nasdaq XOMA, biotechnology, royalty aggregator